Prostate cancer, Internal medicine, Cancer biomarkers, Oncology and Cancer research are his primary areas of study. The study incorporates disciplines such as Prostate and Docetaxel in addition to Prostate cancer. His study in Internal medicine is interdisciplinary in nature, drawing from both Endocrinology and Surgery.
His Cancer biomarkers research includes themes of Androgen Receptor Antagonists, Disease, Immunology and Circulating tumor cell. His Oncology research integrates issues from Neoplasm, Androgen deprivation therapy and Phases of clinical research. His Cancer research research is multidisciplinary, relying on both Cancer and Pathology.
Gerhardt Attard mostly deals with Prostate cancer, Internal medicine, Oncology, Cancer biomarkers and Abiraterone acetate. His study focuses on the intersection of Prostate cancer and fields such as Cancer research with connections in the field of Prostate, PTEN and Mutation. His research ties Endocrinology and Internal medicine together.
His Oncology study combines topics in areas such as Abiraterone, Circulating tumor cell, Androgen deprivation therapy, Proportional hazards model and Biomarker. Gerhardt Attard has included themes like Clinical trial, Bioinformatics and Pathology in his Cancer biomarkers study. In Abiraterone acetate, Gerhardt Attard works on issues like Pharmacology, which are connected to CYP17A1 Inhibitor.
Gerhardt Attard mainly focuses on Prostate cancer, Internal medicine, Oncology, Androgen receptor and Enzalutamide. Gerhardt Attard interconnects Taxane, Cancer research and Prednisone in the investigation of issues within Prostate cancer. Gerhardt Attard works mostly in the field of Cancer research, limiting it down to topics relating to Prostate and, in certain cases, Immune system and Metastasis, as a part of the same area of interest.
His Internal medicine and Hazard ratio, Confidence interval, Clinical trial, Apalutamide and Abiraterone investigations all form part of his Internal medicine research activities. His Oncology research is multidisciplinary, incorporating elements of Chemotherapy, Docetaxel, Androgen deprivation therapy, Biomarker and Radiation therapy. The concepts of his Abiraterone acetate study are interwoven with issues in Double blind study and Poly ADP ribose polymerase.
His primary areas of study are Prostate cancer, Internal medicine, Oncology, Hazard ratio and Enzalutamide. His studies in Prostate cancer integrate themes in fields like Evidence synthesis and Cancer research. His research on Internal medicine often connects related topics like Gastroenterology.
The various areas that Gerhardt Attard examines in his Oncology study include Androgen deprivation therapy, Hormone sensitive prostate cancer and Docetaxel. His research investigates the connection between Androgen receptor and topics such as Taxane that intersect with problems in Circulating tumor cell and Blood test. His Randomized controlled trial study which covers Clinical trial that intersects with Visual analogue scale, Placebo, Cancer biomarkers and Metastasis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Integrative clinical genomics of advanced prostate cancer
Dan Robinson;Eliezer M. Van Allen;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz.
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo;Suzanne Carreira;Shahneen Sandhu;Susana Miranda.
The New England Journal of Medicine (2015)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas D. James;Johann S. de Bono;Melissa R. Spears;Noel W. Clarke.
The New England Journal of Medicine (2017)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James;Nicholas D. James;Matthew R. Sydes;Noel W. Clarke;Malcolm David Mason.
The Lancet (2016)
Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
Gerhardt Attard;Alison H.M. Reid;Timothy A. Yap;Florence Raynaud.
Journal of Clinical Oncology (2008)
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Christopher C Parker;Nicholas D James;Christopher D Brawley;Noel W Clarke.
The Lancet (2018)
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
Gerhardt Attard;Alison H.M. Reid;Roger A'Hern;Christopher Parker.
Journal of Clinical Oncology (2009)
Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
Gerhardt Attard;Joost F. Swennenhuis;David Olmos;Alison H.M. Reid.
Cancer Research (2009)
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
G Attard;J Clark;L Ambroisine;G Fisher.
Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
Alison H.M. Reid;Gerhardt Attard;Daniel C. Danila;Nikhil Babu Oommen.
Journal of Clinical Oncology (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: